Experts share what patients should know from the 2026 ASCO GU Cancer Symposium, highlighting biomarkers, trial options and personalized care decisions. As the 2026 ASCO Genitourinary (GU) Cancers ...
Day two of ASCO GU highlighted innovative therapies and the need for better quality-of-life reporting in genitourinary cancer trials. The second day of the 2026 American Society of Clinical Oncology ...
Lower levels of microplastics also detected in most healthy prostate tissue. HealthDay News — Microplastics have been found in most prostate tumors, according to a small study presented at the ...
A range of clinically impactful studies in renal cell carcinoma (RCC), presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium, underscore the growing promise of hypoxia ...
Late-breaking KEYNOTE-B15 data show KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response rates ...
(RTTNews) - Natera Inc. (NTRA) presented new findings at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) on the use of its Signatera molecular residual disease (MRD ...
Impact of treatment approaches on survival in bulky node-positive penile squamous cell carcinoma: A National Cancer Database analysis. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary ...
Dr. Guru Sonpavde, Medical Director of Genitourinary Oncology (GU), AdventHealth Cancer Institute joins the podcast to dive deep into some of the clinical research that AdventHealth is pioneering and ...
ASCO Education: By the Book features engaging discussions between editors and authors from the ASCO Educational Book. Hear nuanced views on topics featured in Education Sessions at ASCO meetings and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results